Loqtorzi 240 mg/6 mL (40 mg/mL) injection Images
Generic Name: toripalimab
This medication has been identified as Loqtorzi 240 mg/6 mL (40 mg/mL) injection. It is supplied by Coherus BioSciences, Inc.
Loqtorzi is used in the treatment of Nasopharyngeal Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Loqtorzi 240 mg/6 mL (40 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Loqtorzi
- Generic Name
- toripalimab
- Strength
- 240 mg/6 mL (40 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Coherus BioSciences, Inc.
- National Drug Code (NDC)
- 70114-0340
More about Loqtorzi (toripalimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
